Diarrhea News and Research

Latest Diarrhea News and Research

Social shame works better than Government subsidies: Study

Government subsidies persuade some people to change habits, but social shame works even better, suggests a recent study of efforts to reduce elevated childhood death and disease rates blamed on the microbial pathogens that cause diarrhea in rural India.

1 Oct 2009

International Medica Foundation sponsors rotavirus vaccine trial in Ghana

More than half a million children – or 1,400 to 1,600 each day – die from rotavirus, the most common cause of severe childhood diarrhea. Almost all of these deaths occur in developing countries, where lifesaving medical care may not be affordable or available to the families with the most critical needs. In addition, income loss due to the need for parents to take care of sick children can have a very significant economic burden on families that can least afford it.

29 Sep 2009

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients.

28 Sep 2009

Pfizer to commence Phase 3 trial of oral c-Met and ALK inhibitor

Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) carrying the ALK (anaplastic lymphoma kinases) fusion gene, who have progressed on one prior treatment with a platinum-based chemotherapy.

26 Sep 2009

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009

European CHMP recommends marketing approval for Sanofi-aventis' Multaq

Sanofi-aventis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Multaq(R) (dronedarone - 400mg Tablets).

26 Sep 2009

WHO lowers expectation of H1N1 vaccine output, appeals for donations to fight pandemic

International drug makers are expected to produce three billion doses of the H1N1 (swine flu) vaccine, "enough for just under half the world's population," a WHO official said Thursday, Canwest News Service/Ottawa Citizen reports. "The agency was hoping pharmaceutical companies would be able to make about five billion doses a year, but data collected over the summer led to the revised estimate," the news service writes (Fitzpatrick, 9/24).

25 Sep 2009

Recent releases in Global Health

A study appearing in the Journal of Infectious Diseases explores how well access to safe drinking water reduces rates of diarrhea experienced by 6-month-old infants born to HIV-infected mothers following weaning.

25 Sep 2009

Safety tips for OTC and prescription medications

The beginning of October marks the start of Talk About Prescriptions Month, which is sponsored by the National Council on Patient Information and Education. In support of this annual awareness effort, Health Net, Inc. (NYSE:HNT) is sharing tips to help consumers safely take over-the-counter (OTC) and prescription medications.

23 Sep 2009

Results of Phase 3 CRYSTAL study of mCRC patients announced

The retrospective CRYSTAL analysis was conducted as a result of an effort to increase the tissue ascertainment rate to determine the K-ras status of patients’ tumors. The analysis included extended patient follow up of nearly 1.5 years and doubled the tissue ascertainment rate from 45% to 89%. These data are an update from the overall survival results from CRYSTAL that were published in the April 2009 issue of the New England Journal of Medicine.

23 Sep 2009

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer.

23 Sep 2009

Phase 1b interim clinical trial results of IMO-2055, Tarceva and Avast combination announced

Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).

23 Sep 2009

Survey: 77% of Latino women avoid milk to manage lactose intolerance

A new Lactose Intolerance in Multicultural Communities Survey sponsored by the LACTAID(R) Brand found that 77 percent of Latinas reduce the amount of milk or dairy in their diet as a way to manage their lactose intolerance. Yet, 63 percent of Latinas who have lactose intolerance worry the condition keeps them from consuming important nutrients, such as calcium and vitamins A and D. Despite their concerns, only 14 percent have talked to a health care professional about lactose intolerance.

22 Sep 2009

Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy

Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.

22 Sep 2009

Bayer's regorafenib showed 50% stabilization rate in RCC patients

Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC).

22 Sep 2009

Survey: 78% of African American women avoid milk to manage lactose intolerance

A new Lactose Intolerance in Multicultural Communities Survey sponsored by the LACTAID(R) Brand found that 78 percent of African American women reduce the amount of milk or dairy in their diet as a way to manage their lactose intolerance. Yet, 48 percent of African American women who have lactose intolerance worry the condition keeps them from consuming important nutrients, such as calcium and vitamins A and D. Despite their concerns, only 16 percent have talked to a health care professional about lactose intolerance.

22 Sep 2009

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

Data published today in The Lancet showed a survival benefit in nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who received maintenance therapy with ALIMTA(R) (pemetrexed for injection) plus best supportive care as compared to placebo plus best supportive care.

21 Sep 2009

King Pharmaceuticals achieves milestone: Announces commercial availability of EMBEDA

King Pharmaceuticals(R), Inc. (NYSE: KG) today announced a true milestone as it marks the first commercial availability for EMBEDA(TM) (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules, a long-acting Schedule II opioid analgesic for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

21 Sep 2009

H1N1 infected people continue to shed live virus days after the symptoms

ABC News and other outlets are reporting that two studies released on Tuesday suggest that people infected with the H1N1 virus continue to shed virus after the point where current recommendations say they can resume their normal activities.

19 Sep 2009

Pfizer Oncology to present early-stage research of investigational agents for cancer treatment

Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer, updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET), and early-stage research of investigational agents PF-02341066 and figitumumab (CP-751,871) in patients with non-small cell lung cancer (NSCLC).

19 Sep 2009

Diarrhea News and Research

Latest Diarrhea News and Research

Social shame works better than Government subsidies: Study

International Medica Foundation sponsors rotavirus vaccine trial in Ghana

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Pfizer to commence Phase 3 trial of oral c-Met and ALK inhibitor

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

European CHMP recommends marketing approval for Sanofi-aventis' Multaq

WHO lowers expectation of H1N1 vaccine output, appeals for donations to fight pandemic

Recent releases in Global Health

Safety tips for OTC and prescription medications

Results of Phase 3 CRYSTAL study of mCRC patients announced

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

Phase 1b interim clinical trial results of IMO-2055, Tarceva and Avast combination announced

Survey: 77% of Latino women avoid milk to manage lactose intolerance

Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy

Bayer's regorafenib showed 50% stabilization rate in RCC patients

Survey: 78% of African American women avoid milk to manage lactose intolerance

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

King Pharmaceuticals achieves milestone: Announces commercial availability of EMBEDA

H1N1 infected people continue to shed live virus days after the symptoms

Pfizer Oncology to present early-stage research of investigational agents for cancer treatment

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Diarrhea News and Research

Latest Diarrhea News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in